Issue 4, 2012

Largazole: From discovery to broad-spectrum therapy

Abstract

Covering up to 2011

The cyclic depsipeptide largazole from a cyanobacterium of the genus Symploca is a marine natural product with a novel chemical scaffold and potently inhibits class I histone deacetylases (HDACs). Largazole possesses highly differential growth-inhibitory activity, preferentially targeting transformed over non-transformed cells. The intriguing structure and biological activity of largazole have attracted strong interest from the synthetic chemistry community to establish synthetic routes to largazole and to investigate its potential as a cancer therapeutic. This Highlight surveys recent advances in this area with a focus on the discovery, synthesis, target identification, structure–activity relationships, HDAC8–largazole thiol crystal structure, and biological studies, including in vivo anticancer and osteogenic activities.

Graphical abstract: Largazole: From discovery to broad-spectrum therapy

Supplementary files

Article information

Article type
Highlight
Submitted
01 Sep 2011
First published
14 Feb 2012

Nat. Prod. Rep., 2012,29, 449-456

Largazole: From discovery to broad-spectrum therapy

J. Hong and H. Luesch, Nat. Prod. Rep., 2012, 29, 449 DOI: 10.1039/C2NP00066K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements